Ixazomib
AGMT_MBC-10 (X16087)
Phase 2 small_molecule terminated
Quick answer
Ixazomib for Triple-Negative Breast Cancer is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Triple-Negative Breast Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated